Skip to main content
Premium Trial:

Request an Annual Quote

France's Polyplus-transfection Licenses Oligonucleotide Tech to Metabion

Premium

French biotech firm Polyplus-transfection said this week that it has non-exclusively licensed its modified oligonucleotide technology to Germany's Metabion.

The agreement covers Polyplus' Zip Nucleic Acid oligonucleotides, which are modified oligonucleotides that have increased affinity for nucleic acids while retaining specificity.

Under the agreement, Metabion will be able to manufacture and commercialize custom ZNA oligonucleotides for research and in vitro diagnostics applications. Metabion, based in the Munich area, will begin commercializing the custom products later this month.

Polyplus, based in Strasbourg, said that its ZNA oligonucleotides, when used as primers or probes, improve the performance of molecular hybridization techniques such as PCR assays. ZNAs also increase the sensitivity of tests and detection of mutations, the company said.

Polyplus has also licensed its ZNA oligonucleotides to Sigma-Aldrich.

In December, Polyplus said that it raised €1.2 million ($1.8 million at the time) through a new funding round from existing investors; and said that it planned to add a new CEO and business development manager for its US operations.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.